Argent Biopharma Limited Additional Information for Shareholders
December 16 2024 - 3:13AM
RNS Non-Regulatory
RNS Number : 2117Q
Argent Biopharma Limited
16 December 2024
16
December 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
Additional Information for
Shareholders
Argent BioPharma, an innovative
multidisciplinary drug discovery company within the
biopharmaceutical sector, wishes to provide holders of the
Company's Depositary Interests (DIs) further information regarding
their shareholding following the Company's delisting from the Main
Market of the London Stock Exchange (LSE).
Upon the delisting event, Argent's
shares will cease to be admitted to trading on the LSE, removing
the ability to trade through the exchange. The DIs will still be
able to settle through the CREST system, which will allow for the
depositary interests to be withdrawn from the CREST system and
transferred into the Clearing House Electronic Sub-register System
(CHESS) which facilitates
trade settlements on the Australian Stock Exchange (ASX). DI holders will be
contacted separately regarding any potential future termination of
the Depositary Interest facility but should note that in order to
settle any trades placed on the ASX they will need to withdraw
their DIs and reposition to CHESS, the process for which remains
unchanged as a result of the delisting.
The delisting is anticipated to be
effective from 08:00 (GMT) on Tuesday, 31 December 2024. The last
day of trading of Argent BioPharma shares on the LSE will be
Tuesday, 31 December 2024.
Any shareholder that has additional
queries around trading is encouraged to approach their investment
adviser or broker.
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About Argent BioPharma
Argent BioPharma Limited (the
"Company") (ASX: RGT; LSE:
RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development
Company within the biopharmaceutical sector. The Company
focuses on multidisciplinary methods with Nanotechnology,
developing multi-target therapies for comprehensive disease
management, especially concerning the central nervous system
("CNS") and Immunology treatments.
Follow us through our social media
channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent
BioPharma
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRAEAPAKFFALFEA
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Dec 2023 to Dec 2024
